Abstract
The present invention relates to therapeutic antibodies for the treatment of cancer, and more specifically, for the treatment of prostate, bladder, and/or pancreatic cancer. An embodiment of the present invention is an anti-glypican-1 (GPC 1) antibody, which may be conjugated to at least one cytotoxic agent that is toxic to a prostate, bladder, and/or pancreatic cancer cell.
| Original language | English |
|---|---|
| Patent number | AU2016250900 |
| IPC | C07K 16/28,A61K 39/395,A61P 35/00,C07K 16/30 |
| Priority date | 20/04/15 |
| Filing date | 20/04/16 |
| Publication status | Submitted - 20 Apr 2016 |